Evidence map›Paper›PMID 24057354›Full record

SynthesisKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2015

Tendon healing: an overview of physiology, biology, and pathology of tendon healing and systematic review of state of the art in tendon bioengineering.

Sebastian A Müller, Atanas Todorov, Patricia E Heisterbach, Ivan Martin, Martin Majewski

2 registry-linked trialsAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02298023 phase2completednot on this map

Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.

TypeinterventionalSponsorSeoul National University HospitalRan2014 to 2018Enrolled24ConditionsRotator Cuff TearArmsallogenic adipose stem cell injection, fibrin glue/normal saline injection, normal saline injection
NCT03449082 phase2completednot on this mapstarted 2018, after this paper: background citation

Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial

TypeinterventionalSponsorSeoul National University HospitalRan2018 to 2021Enrolled30ConditionsLateral EpicondylitisArmsHigh concentration of Allo-ASC, Low concentration of Allo-ASC, Fibrin glue, Normal saline
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 151 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Insulin-like growth factor-1 (IGF-1) empowering tendon regenerative therapies.Frontiers in bioengineering and biotechnology · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sebastian A MüllerDepartment of Orthopedic Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland, muellerse@uhbs.ch.
Atanas Todorov
Patricia E Heisterbach
Ivan Martin
Martin Majewski
University Hospital of Basel · CHDepartment of Biomedicine Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTendon injuries vary from acute rupture to chronic tendinopathy. For an optimal treatment of either condition, a profound knowledge is essential. Therefore, this article shall give an overview of physiology, biology, and pathology of tendon healing and state of the art in tendon bioengineering.

methodsFor a preferably comprehensive survey, the current literature listed in PubMed and published in English peer-reviewed journals (March 2013) was systematically reviewed for tendon healing and tendon bioengineering including cytokine modulation, autologous sources of growth factors, biomaterials, gene therapy, and cell-based therapy. No differentiation was made between clinical and preclinical in vitro investigations.

resultsTendon healing happens in certain stadiums of inflammation, formation, and remodelling. An additional process of "collagen recycling" close to the healing site has been described recently. With increasing comprehension of physiology and pathology of tendon healing, several promising approaches in tendon bioengineering using growth factors, biomaterials, gene therapy, or cell-based therapy are described. However, only some of these are already used routinely in clinics.

conclusionStrong and resistant tendons are crucial for a healthy musculoskeletal system. The new approaches in tendon bioengineering are promising to aid physiological tendon healing and thus resulting in a stronger and more resistant tendon after injury. The growing knowledge in this field will need to be further taken into clinical studies so that especially those patients with prolonged courses, revision surgery, or chronic tendinopathy and high-demanding patients, i.e., professional athletes would benefit. LEVEL OF EVIDENCE: II.

Indexed as

BioengineeringBiocompatible MaterialsCell- and Tissue-Based TherapyCollagenCytokinesGenetic TherapyHumansInflammationIntercellular Signaling Peptides and ProteinsRuptureTendinopathyTendon InjuriesWound HealingBiocompatible MaterialsCollagenCytokinesIntercellular Signaling Peptides and Proteins

Identifiers

PMID24057354
OpenAlexW2027519024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.